1
Participants
Start Date
August 7, 2019
Primary Completion Date
March 1, 2023
Study Completion Date
February 1, 2024
Pregabalin
Pregabalin /placebo capsules will be taken by mouth and will be prescribed for the study participants in the doses, depending on their weight and treatment phase: Participant \< 25 kg at baseline will start with 50 mg per day, increasing the dose by 50 mg each week until their maximum dose 200 mg per day; Participants who are greater than or equal to 25 kg at baseline will start with 100 mg per day, increasing their dose by 50 mg each week until their target dose 300 mg per day is achieved. The study medication will be taken twice per day.The dose will be weaned down every 1-2 days by 25 mg in the last two weeks of each treatment period.
The Hospital for Sick Children, Toronto
Epidemolysis Bullosa Research Partnership
OTHER_GOV
The Hospital for Sick Children
OTHER